Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. RAD51C is a less commonly studied ovarian cancer susceptibility gene whose promoter is sometimes methylated, leading to homologous...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurley, Rachel M, McGehee, Cordelia D, Nesic, Ksenija, Correia, Cristina, Weiskittel, Taylor M, Kelly, Rebecca L, Venkatachalam, Annapoorna, Hou, Xiaonan, Pathoulas, Nicholas M, Meng, X Wei, Kondrashova, Olga, Radke, Marc R, Schneider, Paula A, Flatten, Karen S, Peterson, Kevin L, Becker, Marc A, Wong, Ee Ming, Southey, Melissa S, Dobrovic, Alexander, Lin, Kevin K, Harding, Thomas C, McNeish, Iain, Ross, Christian A, Wagner, Jill M, Wakefield, Matthew J, Scott, Clare L, Haluska, Paul, Wahner Hendrickson, Andrea E, Karnitz, Larry M, Swisher, Elizabeth M, Li, Hu, Weroha, S John, Kaufmann, Scott H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Cancer Gene Regulation, Chromatin, and Epigenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271218/
https://www.ncbi.nlm.nih.gov/pubmed/34316715
http://dx.doi.org/10.1093/narcan/zcab028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271218/
https://www.ncbi.nlm.nih.gov/pubmed/34316715
http://dx.doi.org/10.1093/narcan/zcab028

Ejemplares similares